We have previously shown that the PAM50-based risk of recurrence ( ROR ) score is significantly correlated with distant recurrence in both the translational research cohort within the Arimidex , Tamoxifen Alone or in Combination ( ATAC ) trial ( TransATAC ) and Austrian Breast and Colorectal Cancer Study Group 8 ( ABCSG 8 ) randomized trials .